" I’m convinced beyond a doubt if we are able to see in the clinical trials even a portion of the results that we’ve seen in the lab studies, Cellceutix will experience a wave of unprecedented growth. "

The market is so big for Kevetrin with the variety of cancers that it could potentially treat, that even low efficacy would be an improvement since Kevetrin would be used in combination therapy.  It would add to the effectiveness of treatment and possibly lower combination therapy side effects.  Setting the bar low is always good so that you under promise and over deliver.  That's the best policy for public companies.